Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL4I1+ Macrophage Accumulation in Advanced Cutaneous T-Cell Lymphomas Suggests a Role in Tumor Immune Escape.

The Journal of investigative dermatology·2026
Same author

French national protocol for diagnosis and management of pemphigoid gestationis.

Annales de dermatologie et de venereologie·2026
Same author

French national protocol for diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in adults and children.

Annales de dermatologie et de venereologie·2025
Same author

Retrospective study on the association of human herpesvirus reactivation with severe DRESS: A description of blood and skin reactivations.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

IgA and IgG/IgA intercellular dermatosis: a clinicopathological case series of 15 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Calcinosis cutis in epidermal necrolysis: role of caspofungin?

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

[Methotrexate-induced cutaneous reactions: two case reports].

M Al Mebayadh1, A Cosnes, N Ortonne

  • 1Service de dermatologie, centre de référence des maladies bulleuses immunologiques et toxiques, université Paris-Est Créteil (UPEC), hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France.

Annales De Dermatologie Et De Venereologie
|June 23, 2012
PubMed
Summary
This summary is machine-generated.

Methotrexate can cause rare skin reactions in dermatological patients. These cases highlight unusual rashes, emphasizing the need to consider methotrexate side effects in recurrent skin issues.

More Related Videos

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
04:12

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

Published on: January 19, 2024

Related Experiment Videos

Last Updated: May 21, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
04:12

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

Published on: January 19, 2024

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Methotrexate is a long-standing treatment for dermatological conditions.
  • Cutaneous side effects are uncommon, typically linked to overdose.

Observation:

  • Two patients with bullous pemphigoid developed distinct skin rashes after initiating methotrexate therapy.
  • Case 1: A 70-year-old male presented with a vesicular, itchy rash on the face and trunk.
  • Case 2: An 81-year-old female developed an edematous, papular eruption on her face.

Findings:

  • Both patients experienced rashes that recurred with subsequent methotrexate intake.
  • Lesions improved significantly after reducing the methotrexate dosage.
  • The clinical presentation of these methotrexate-induced cutaneous adverse reactions was atypical.

Implications:

  • These cases underscore the importance of considering methotrexate as a potential cause of unexpected cutaneous adverse reactions.
  • Systematic evaluation for methotrexate-induced rashes is crucial in patients with recurrent or atypical skin eruptions.
  • The findings suggest that careful dosage management can mitigate methotrexate-related dermatological side effects.